Mycofin spray dermal 10 mg/g, 30 ml — Made in Turkey — Free Delivery

Name: Mycofin spray dermal 10 mg/g, 30 ml — Made in Turkey — Free Delivery
Brand: Nobel Ilac San. Ve Tic. A.S.
Price: 25.1785 USD
Availability: InStock
Rating: 5 (1 reviews)

Brand: Nobel Ilac San. Ve Tic. A.S.
Product Code: Mycofin
Availability: In Stock

$25.18

Add to Cart

Description

Indications

Onychomycosis (fungal infection of the nails) caused by dermatophyte fungi.

Mycosis of the scalp.

Fungal infections of the skin - treatment of trichophytosis of the smooth skin, perineum, ringworm and yeast infections of the skin caused by fungi of the genus Candida (eg C. albicans).

Pityriasis versicolor (Mikofin spray, cream).

Application

Orally. the duration of the course of treatment and the dosage regimen are set individually and depend on the localization of the process and the severity of the disease.

Adults are usually prescribed Mycofin 1 tablet (250 mg) 1 time per day.

For children, the preparation is prescribed over the age of 6 years. The dose depends on the body weight of the child and is: for children weighing 20-40 kg - 125 mg (½ tablet 250 mg) 1 time per day; 40 kg - 250 mg 1 time per day.

Duration of treatment:

tinea pedis (interdigital, plantar or sock type) - 2-6 weeks;
trichophytosis of smooth skin, perineum - 2-4 weeks;
candidiasis of the skin and mucous membranes - 2-4 weeks;
mycosis of the scalp - about 4 weeks.

The complete disappearance of the clinical manifestations of the disease is noted, as a rule, a few weeks after treatment.

With onychomycosis, the duration of treatment with Mycofin is 6-12 weeks. With onychomycosis of the upper extremities, the course of treatment is 6 weeks, and with onychomycosis of the lower extremities - 12 weeks. The optimal clinical effect appears a few months after cessation of therapy. This is determined by the period necessary for the growth of a healthy nail.

Outdoor use

Cream. Terbinafine is applied in a thin layer to the affected areas of the skin 1-2 times a day and gently rubbed. For infections that are accompanied by diaper rash (under the mammary glands, in the interdigital spaces, between the buttocks, in the inguinal region), the places where the cream is applied can be covered with gauze, especially at night.

Duration of treatment:

ringworm of the trunk and extremities - 1 time per day for a week;
skin candidiasis - 1-2 times a day for 1-2 weeks;
multi-colored lichen - 1-2 times a day for 2 weeks.

A decrease in the severity or disappearance of the main symptoms of the disease is usually noted in the first days of therapy. In case of irregular treatment or its premature termination, there is a risk of relapse. There is no experience of using the preparation for the treatment of children under the age of 12 years.

The spray can be used 1-2 times a day, depending on the indications. Before use, thoroughly clean and dry the affected areas of the skin. The preparation is sprayed onto the affected areas in an amount sufficient to thoroughly moisturize them. In addition, the spray should also be applied to nearby areas of intact skin.

Duration of treatment and frequency of use:

ringworm of the feet - 1 time per day for a week;
dermatomycosis of the trunk, legs - 1 time per day for a week;
multi-colored lichen - 2 times a day for a week.

There is insufficient experience with the topical spray in children. For elderly patients, dose adjustment is not required.

Contraindications

Hypersensitivity to terbinafine or other components of the preparation; chronic heart failure.

Side effects

When taking the tablet form, you may notice:

from the gastrointestinal tract: dyspepsia, abdominal pain, feeling of fullness in the stomach, nausea, loss of appetite, diarrhea;
from the hepatobiliary system: hepatobiliary dysfunction, including jaundice, cholestasis and hepatitis. In very rare cases, severe liver failure. In most cases of liver failure in patients, systemic disorders of the condition have already been noted, and the relationship with taking terbinafine was doubtful;
from the musculoskeletal system: muscle pain, joint pain;
from the hematopoietic system: neutropenia, agranulocytosis, thrombocytopenia, rarely - lymphopenia;
from the immune system: anaphylactoid reactions (including angioedema), skin and systemic manifestations of lupus erythematosus;
from the nervous system: headache, impaired sense of taste, including loss of taste, which usually recovers after discontinuation of the preparation, dizziness, paresthesia and hypoesthesia;
on the part of the organ of hearing and the labyrinth: vertigo;
mental disorders: depression, anxiety;
on the part of the skin and subcutaneous tissues: mild forms of skin reaction (rashes, urticaria), skin rashes in the form of spots, blisters, severe skin reactions (Stevens-Jones syndrome, toxic epidermal necrolysis, photosensitivity), acute generalized exanthematous pustulosis, psoriasis-like rashes and exacerbation psoriasis, hair loss, although a causal relationship has not been proven;
general disorders: increased fatigue.

In places where the spray and cream are applied, redness, itching or burning sensation may occur, which, as a rule, do not require discontinuation of treatment. These not very serious side effects should be distinguished from allergic reactions that occur rarely, but the development of which requires discontinuation of treatment.

special instructions

Mycofin Spray and Cream is for external use only. spray should be avoided in the eyes. clinical experience with the use of spray and cream in women during pregnancy is limited, therefore, before prescribing the preparation, it is necessary to weigh the expected benefit to the mother and the potential risk to the fetus or child. Terbinafine passes into breast milk in small amounts, so the cream and spray should not be used during breastfeeding. the tablet form of mycofin is not recommended for patients with chronic or acute liver damage. before prescribing terbinafine, it is necessary to assess the condition of a patient with liver disease.

Hepatotoxicity may be noted with or without prior liver injury. Patients taking terbinafine should be warned about the need to immediately inform the doctor in case of nausea of unknown origin, anorexia, fatigue, vomiting, jaundice, pain in the upper abdomen, dark urine or light-colored stools.

In the event of progressive skin rashes, terbinafine should be discontinued immediately.

In the event of any pathological change in the blood in a patient taking terbinafine, a change in preparation treatment should be recommended.

In patients with reduced renal function (creatinine clearance of 50 ml / min or plasma creatinine greater than 300 μmol / l), the use of terbinafine has not been studied, therefore, such patients are not recommended to use the preparation.

Children. Terbinafine is administered orally to children over 6 years of age and weighing over 20 kg, spray and cream - to children over 12 years of age.

During pregnancy and breastfeeding. The experience of using the tablet form of the preparation during pregnancy is limited, therefore, during pregnancy, the preparation can be used only if the expected benefit to the mother outweighs the potential risk to the fetus. Terbinafine passes into breast milk, therefore, if necessary, the use of the preparation for the period of treatment should stop breastfeeding.

Interactions

Effect of other preparations on terbinafine. Plasma clearance of terbinafine may be increased by preparations that induce metabolism and may be decreased by preparations that inhibit cytochrome p450. if concomitant treatment with such preparations is necessary, the dose of terbinafine should be adjusted.

Preparations affecting plasma concentrations of terbinafine. Rifampicin increases the clearance of terbinafine by 100%. The total clearance of terbinafine may be slowed down by preparations- inhibitors of the cytochrome P450 system (cimetidine).

Effect of terbinafine on other preparations. The results of studies have shown that terbinafine has little potential to inhibit or increase the clearance of preparations metabolized with the participation of cytochrome P450 (cyclosporine, terfenadine, triazolam, tolbutamide or oral contraceptives). Terbinafine affects the clearance of antipyrine or digoxin.

In patients who simultaneously take Mycofin and oral contraceptives, menstrual irregularities may be noted.

Mycofin cream should not be used concomitantly with other creams.

Overdose

In case of overdose when administered orally (taking up to 5 g of the preparation), nausea, pain in the epigastric region, dizziness, headache are possible.

Treatment is symptomatic, excretion of the preparation, primarily by taking activated charcoal, gastric lavage. Cases of overdose of cream and spray have not been recorded.

Storage conditions

In a dry, dark place, at a temperature not exceeding 25 ° C.

1 reviews

h...n

04/10/2022

text_comment

Good product, effective. I recommend